Today: 19 March 2026
Subscribe
Browse Category

NASDAQ:W 28 October 2025 - 4 January 2026

Venezuela, Fed bets and jobs data loom: What to know before U.S. stocks open Monday

Venezuela, Fed bets and jobs data loom: What to know before U.S. stocks open Monday

President Donald Trump said the U.S. has captured Venezuelan President Nicolas Maduro and will take temporary control of Venezuela. The Dow rose 0.66% Friday, S&P 500 edged up, and Nasdaq slipped. Oil prices are expected to rise after the announcement. Investors await the Jan. 9 U.S. jobs report and Jan. 13 CPI and JPMorgan results.
4 January 2026
·······
Dow Jones today: Friday rebound lifts the Dow ahead of ISM and jobs data

Dow Jones today: Friday rebound lifts the Dow ahead of ISM and jobs data

The Dow Jones rose 319 points, or 0.7%, to 48,382.39 on Friday, ending a four-day slide as chip and industrial stocks advanced. Tesla fell 2.6% after reporting a second consecutive annual sales drop. The S&P 500 closed at 6,858.47, Nasdaq at 23,235.63. Investors now await Monday’s ISM manufacturing data and Friday’s U.S. jobs report.
4 January 2026
······
U.S. stocks brace for Venezuela shock after Trump strike; key jobs report next

U.S. stocks brace for Venezuela shock after Trump strike; key jobs report next

U.S. forces struck Venezuela and captured President Nicolas Maduro over the weekend, with markets set to react when trading opens Monday. The Dow and S&P 500 closed higher Friday, while oil prices slipped ahead of the news. Trump said the U.S. will oversee a transition in Venezuela and allow major oil firms to enter. Maduro is expected in Manhattan federal court Monday, according to officials.
4 January 2026
······
Stock market today: S&P 500, Nasdaq start 2026 higher as tech rebounds; Intuit sinks on co-founder sale

Stock market today: S&P 500, Nasdaq start 2026 higher as tech rebounds; Intuit sinks on co-founder sale

U.S. stocks opened 2026 higher, with the S&P 500 up 0.38% and the Nasdaq gaining 0.75% by midmorning, led by large technology shares. Intuit dropped 5.3% after a filing showed co-founder Scott Cook sold $50 million in stock. Nvidia and Broadcom rose, while furniture retailers gained after President Trump delayed some tariffs. European and Asian markets also advanced; oil fell over 1%.
2 January 2026
······
Stock market today: Nasdaq, S&P 500 futures climb to start 2026 as Nvidia and Baidu rally

Stock market today: Nasdaq, S&P 500 futures climb to start 2026 as Nvidia and Baidu rally

Nasdaq 100 E-minis rose 1.05% and S&P 500 E-minis gained 0.60% in premarket trading Friday, led by rebounds in Nvidia and Broadcom. Baidu jumped 12% after its AI chip unit Kunlunxin filed for a Hong Kong IPO. Tesla rose over 2% ahead of delivery figures. The White House delayed tariff hikes on imported furniture for a year.
2 January 2026
·······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 28.10.2025

Colgate-Palmolive shares fell 3% in the past month, with a 1-year total return of -16.6% despite steady earnings. Agilysys and Wayfair hit 52-week highs after beating estimates and raising guidance. U.S. stocks closed near records Oct. 28; ReNew Energy Global surged 241% while Co-Diagnostics plunged 55%. American Bitcoin (ABTC) dropped 5% during a volatile week.
28 October 2025
····

Stock Market Today

  • Pelthos Therapeutics Q4 Loss Narrower Than Expected, Revenue Beats Estimates
    March 19, 2026, 9:26 AM EDT. Pelthos Therapeutics Inc. (PTHS) reported a Q4 loss of $2.83 per share, narrower than the Zacks Consensus Estimate of a $3.95 loss and improved from a $3.2 loss last year. The company posted $9.39 million in revenue, beating estimates by 3.78%, marking its first revenue in a year. Despite this, shares have fallen 22.3% year-to-date, underperforming the S&P 500. The stock holds a Zacks Rank #5 (Strong Sell) reflecting unfavorable earnings outlook and estimate revisions. Consensus estimates predict a loss of $3.84 per share next quarter on $9.86 million revenue and a $10.80 loss for the fiscal year on $62.29 million revenue. Market performance depends on management commentary and industry trends within the Medical - Biomedical and Genetics sector, currently ranked in the bottom 43% of Zacks industries.
Go toTop